Related Experiment Video
Updated: Jun 25, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario
Irene Miniati1, Gabriele Valentini, Marco Matucci Cerinic
1Department of Biomedicine, Division of Rheumatology AOUC, Denothe Center, University of Florence, Viale Pieraccini 18, 50139 Florence, Italy.
Abstract:
In systemic sclerosis (SSc), there is no proven treatment to prevent disease progression. In a recent meta-analysis of three randomised controlled trials (RCTs) and six open prospective studies on cyclophosphamide (CYC), no significant changes in lung function were observed. However, CYC is associated with an improvement of Mahler's dyspnea index, short form-36 (physical and mental domains), and health-related quality of life, contributing to the amelioration of patients' functional status. Further RCTs on early SSc are needed to assess the real efficacy of CYC in inducing remission and increasing survival.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Nephrotic Syndrome I : Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF